Peficitinib improves bone fragility by recovering bone turnover imbalance in arthritic mice

Peficitinib, a pan-JAK inhibitor, is known to suppress the activation of fibroblast-like synoviocytes (FLSs) and thereby reduces joint inflammation associated with rheumatoid arthritis (RA). However, the effect on osteoporosis in RA remains to be elucidated. In this study, the effect of peficitinib...

Description complète

Détails bibliographiques

Auteurs principaux:	Shingo Sugahara, Kaori Hanaoka, Takashi Emori, Nobuaki Takeshita, Yasutomo Fujii, Masaki Nakano, Takako Suzuki, Jun Takahashi, Yukio Nakamura
Format:	Artigo
Langue:	Inglês
Publié:	Elsevier 2022-01-01
Collection:	Journal of Pharmacological Sciences
Sujets:	Arthritis Osteoporosis Osteoclast/osteoblast biology Peficitinib Bone density
Accès en ligne:	http://www.sciencedirect.com/science/article/pii/S1347861321001018
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!